An mGlu4‐Positive Allosteric Modulator Alleviates Parkinsonism in Primates
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder that typically presentsbetween the ages of 35 and 50, with a range of clinical manifestations including motor, cognitive and psychiatric impairments
Anatomo‐Functional Mapping of the Primate Mesencephalic Locomotor Region Using Stereotactic Lesions
Injection of HD patient-derived homogenates leads to propagation of mHTT in WT mice but does not induce behavioural changes. Injection of HD patient-derived homogenates exacerbates cognitive deficits in BACHD mice and induces localized aggregation. Injection of HD patient-derived homogenates does not change behaviour of Macaques despite long-term presence of aggregates. Injection of HD patient-derived homogenates does not change endogenous HTT in any of the tested conditions.
Patients with Parkinson's disease (PD) display significant sleep disturbances and daytime sleepiness. Dopaminergic treatment dramatically improves PD motor symptoms, but its action on sleep remains controversial, suggesting a causal role of nondopaminergic lesions in these symptoms.